- Home
- AIRS vs NKTR Comparison
AIRS vs NKTR Comparison
Compare AIRS & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRS
- NKTR
- Stock Information
- Founded
- AIRS 2012
- NKTR 1990
- Country
- AIRS United States
- NKTR United States
- Employees
- AIRS N/A
- NKTR N/A
- Industry
- AIRS Medical/Nursing Services
- NKTR Biotechnology: Pharmaceutical Preparations
- Sector
- AIRS Health Care
- NKTR Health Care
- Exchange
- AIRS Nasdaq
- NKTR Nasdaq
- Market Cap
- AIRS 400.5M
- NKTR 247.9M
- IPO Year
- AIRS 2021
- NKTR 1994
- Fundamental
- Price
- AIRS $5.35
- NKTR $0.93
- Analyst Decision
- AIRS Hold
- NKTR Buy
- Analyst Count
- AIRS 2
- NKTR 3
- Target Price
- AIRS $5.00
- NKTR $4.00
- AVG Volume (30 Days)
- AIRS 248.7K
- NKTR 2.3M
- Earning Date
- AIRS 11-08-2024
- NKTR 11-07-2024
- Dividend Yield
- AIRS N/A
- NKTR N/A
- EPS Growth
- AIRS N/A
- NKTR N/A
- EPS
- AIRS N/A
- NKTR N/A
- Revenue
- AIRS $188,780,000.00
- NKTR $93,137,000.00
- Revenue This Year
- AIRS N/A
- NKTR $12.85
- Revenue Next Year
- AIRS $10.31
- NKTR N/A
- P/E Ratio
- AIRS N/A
- NKTR N/A
- Revenue Growth
- AIRS N/A
- NKTR 5.53
- 52 Week Low
- AIRS $2.92
- NKTR $0.47
- 52 Week High
- AIRS $9.20
- NKTR $1.93
- Technical
- Relative Strength Index (RSI)
- AIRS 38.88
- NKTR 33.04
- Support Level
- AIRS $5.58
- NKTR $0.89
- Resistance Level
- AIRS $6.60
- NKTR $1.04
- Average True Range (ATR)
- AIRS 0.58
- NKTR 0.07
- MACD
- AIRS -0.15
- NKTR -0.00
- Stochastic Oscillator
- AIRS 0.43
- NKTR 14.81
About AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. At Elite Body Sculpture, company provide custom body contouring using proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure.
About NKTR Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.